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Open access under the ElsMeso-tetra-(N-methylpiridinium-4-yl)-porphyrin (TMPyP) and meso-tetra-(4-sulfonatophenyl)-porphy-
rin (TPPS4) are photosensitizing drugs (PS) used in photodynamic therapy (PDT). Based on the fact that
these compounds present similar chemical structures but opposite charges at pH levels near physiolog-
ical conditions, this work aims to evaluate the in vitro and in vivo inﬂuence of these electrical charges on
the iontophoretic delivery of TMPyP and TPPS4, attempting to achieve maximum accumulation of PS in
skin tissue. The iontophoretic transport of these drugs from a hydrophilic gel was investigated in vitro
using porcine ear skin and vertical, ﬂow-through diffusion cells. In vivo experiments using rats were also
carried out, and the penetration of the PSs was analyzed by ﬂuorescence microscopy to visualize the
manner of how these compounds were distributed in the skin after a short period of iontophoresis appli-
cation. In vitro, both passive and iontophoretic delivery of the positively charged TMPyP were much
greater (20-fold and 67-fold, respectively) than those of the negatively charged TPPS4. TPPS4 iontophore-
sis in vivo increased the ﬂuorescence of the skin only in the very superﬁcial layers. On the other hand,
iontophoresis of the positively charged drug expressively increased the rat epidermis and dermis ﬂuores-
cence, indicating high amounts of this drug throughout the skin layers. Moreover, TMPyP was homoge-
neously distributed around and into the nuclei of the skin cells, suggesting its potential use in topical PDT.
 2010 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Photodynamic therapy (PDT) is a currently studied treatment
for neoplasic diseases. It involves the administration of a photosen-
sitizing drug (PS) that preferentially accumulates in target tissues
[1]. After PS accumulation, the tumoral lesion is irradiated with se-
cure doses of visible light that activates the drug and in the pres-
ence of oxygen generates cytotoxic and reactive oxygen species,
such as singlet oxygen, hydroxyl radicals, superoxide anions and
hydrogen peroxide. The presence of these toxic species will cause
cell death in the neoplastic tissue [2,3]. A topical administration
of PSs is well suited for the treatment of skin tumors by PDT
because it would deliver the drug into the pathological site to
increase the local bioavailability of the PS and reduce the occur-
rence of systemic side effects during treatment.
5-Aminolevulinic acid (ALA), a precursor of endogenous PS pro-
toporphyrin IX (PpIX), is the most studied drug in topical PDT. Due
to its relatively low molecular weight (168 Da), ALA can penetrate
damaged skin rather easily, leading to PpIX accumulation,l Sciences of Ribeirão Preto,
ibeirão Preto, SP, Brazil. Tel./
).
evier OA license.especially in tumor cells [1]. However, there are many variables
that may interfere with PpIX local bioavailability, such as irregular
ALA skin penetration, dependence on the quantity of pro-drug that
penetrates the skin and the local metabolism of ALA conversion in
PpIX, and heterogeneous distribution of ALA-induced PpIX in the
tumor [1]. Therefore, the direct administration of a PS instead of
a pro-drug could be advantageous because the drug would already
be photosensitive and would not be dependent on skin metabolism
for conversion into an active molecule [4].
Porphyrins belong to a very important class of PS used in PDT by
parenteral administration [5]. Although Photofrin, a non-charged
porphyrin, is most often used in the PDT of tumors, charged
porphyrins also have several interesting features that make them
attractive for PDT. Meso-tetra-(N-methylpyridinium-4-yl)-porphy-
rin (TMPyP) (Fig. 1A), for instance, is a cationic water soluble
porphyrin that is known to accumulate in tumors with a good
degree of selectivity [6,7]. Since the positive charges of the TMPyP
side chains are appropriate for electrostatic interactions with the
negative charges of nucleic acids, TMPyP can promote high rates
of tumor necrosis and has been shown to increase the survival of
tumor-bearing animals [6–9]. Also, in vitro studies showed that
cationic porphyrins are able to intercalate between DNA bases,
thus inducing DNA lesions upon photoactivation [6]. Meso-
tetra-(4-sulfonatophenyl)-porphyrin (TPPS4) (Fig. 1B), ﬁrst used
Fig. 1. Chemical structure of (A) TMPyP and (B) TPPS4.
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that is water soluble at room temperature and provides a great
yield of singlet oxygen when irradiated [11]. However, when TPPS4
is placed in acidic media, it is protonated and suffers from aggrega-
tion, which drastically changes its spectral and energetic proper-
ties [12]. Furthermore, TPPS4 permeation through the skin is
widely affected by other environmental conditions like concentra-
tion and ionic strength [4]. Aside from the problem of aggregation,
the highly lipophilic nature of the skin restricts the permeation of
these hydrophilic high-molecular-weight charged compounds
through the stratum corneum [13]. To overcome these obstacles,
application of iontophoresis to promote their delivery was
studied.
Iontophoresis is a technique that uses an electrical potential to
maintain a constant low-level electric current (60.5 mA/cm2) to
drive both charged and uncharged compounds into and across
the skin at rates much greater than their passive deliveries
[13–17]. The amount of compound delivered by iontophoresis is
directly proportional to the quantity of charge passed, which
depends on the intensity of the applied current, the duration of
current application and the skin surface exposed to the active elec-
trode compartment [17]. In this way, the topical application of
TMPyP and TPPS4 by iontophoresis could improve the skin perme-
ation of these drugs.
Although iontophoresis of charged molecules has been thor-
oughly studied, the inﬂuence of electrorepulsion for delivering
highly charged molecules (the porphyrins in study have four neg-
atives or four positive charges when ionized) has never been inves-
tigated before aiming a dermal treatment. The most of the studies
involving iontophoresis evaluate the contribution of the electros-
motic ﬂow when molecules opposed in charge are studied, because
these opposite charges are normally obtained with changes in the
pH of the formulation. For instance, amino acids, peptides or pro-
teins [18–20] that have an isoelectric point, or simply weak acids
or bases [21–22], have the pH of their solutions altered to maintain
the drug in the positive or negative form. Because changes in the
solution’s pH can modify electrorepulsive and electroosmotic con-
tributions for the total drug’s ﬂux [17,23], studying the inﬂuence of
these contributions for structurally similar drugs, as the porphy-
rins proposed to be studied in this work (Fig. 1), but opposed in
charge, at a same speciﬁc pH, may assist in the understanding of
topical iontophoretic delivery. It is also important to point that de-
spite the obvious beneﬁts that iontophoresis may offer for the
treatment of a local cutaneous pathology, there have been limited
applications of this technique in the treatment of dermal condi-
tions [17,23]. Therefore, attempts to understand the inﬂuence of
iontophoresis in drug’s skin distribution, and not only in drug’spercutaneous absorption, can contribute for the potential use of
iontophoresis to target the skin.
In this way, the aim of this work was to make use of
iontophoresis to topically deliver TMPyP and TPPS4, evaluating
the inﬂuence of negative and positive charges presented by these
two porphyrin-derivate compounds on their iontophoretic deliver-
ies. This approach was also expected to achieve a high amount and
homogeneous distribution of PS in the skin, which could translate
to progress in topical PDT.
2. Materials and methods
2.1. Materials
TMPyP (TMPyP tetra tosylate salt) and TPPS4 (TPPS4 dihydro-
chloride salt) were obtained from Frontier Scientiﬁc Corporation
(Logan, USA). Ag-wire (99.99%, ø = 1.5 mm), AgCl (99.99%) and
Pt-wire, all used for preparing the Ag/AgCl electrodes [24], were
purchased from Sigma–Aldrich (Steinheim, Germany). Hydroxy-
ethylcellulose (HEC) was purchased from Galena (Campinas,
Brazil) and used for preparing gel formulations by weighting
1.5 g of the polymer and dispersing it in 98.5 g of water. HEPES
was purchased from J.T. Baker (Phillipsburg, USA), NaCl from Synth
(Diadema, Brazil) and Tissue-Tek (O.C.T. Compound) from Sakura
(Toorance, USA). All other reagents were of BDH or HPLC grades.
The water used in all preparations was of Milli-Q grade
(Millipore–France).
2.2. Skin
The skin used for the in vitro experiments was dermatomed
(500 lm) from porcine ear. It was obtained immediately after
slaughter of the animal (Frigoríﬁco Pontal Ltda., Pontal, Brazil)
and stored at 20 C for a maximum of 30 days before use.
2.3. Electrical stability
The electrical current inﬂuence on the stability of the porphyrin
solutions was evaluated prior to the iontophoretic permeation
studies. For this purpose, 10 mL of a TMPyP or TPPS4 aqueous
unbuffered solution at 5.0 mg/mL, containing 89.5 mM NaCl, was
subjected to a current of 0.4 mA by placing them in contact with
the positive (Ag) and negative (AgCl) electrodes connected to a
power supply over 6 h (maximum period of iontophoresis applica-
tion). Samples were collected before and after this experimental
setup, and the TMPyP and TPPS4 spectra in both situations were
analyzed, as well as their pH.
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Experiments were performed in vitro using vertical, ﬂow-
through diffusion cells (LG-1088-IC-Laboratory Glass Apparatus,
Berkeley, CA) and Ag/AgCl electrodes prepared as previously de-
scribed [24]. The area of skin exposed in each electrode chamber
was 0.8 cm2. Dermatomed skin was mounted in the diffusion cell
with the dermal side facing downward into the receiving medium
of 6.0 mL of isotonic buffer (HEPES 25 mmol/L, NaCl 133 mmol/L)
at pH 7.4. For anodal iontophoresis, the anode compartment was
ﬁlled with 1.0 g of the gel formulation containing TMPyP or TPPS4
and the counter-electrode compartment simply contained the iso-
tonic buffer. For cathodal iontophoresis, the cathode was ﬁlled
with 1.0 g of the gel formulation containing TPPS4 and the anode
was ﬁlled with the isotonic buffer. Iontophoretic transport of the
drugs was followed over a period of 6 h at a constant current of
0.5 mA/cm2 generated by a Kepco APH 500DM apparatus (Kepco
Power Supply, USA). The voltage of the complete circuit and of each
cell was measured hourly with a voltmeter (Freak, MY-63) to guar-
antee both the intactness of the skin and that the Ag/AgCl electrode
reactions were occurring as expected.
During the experiments, the receiving solution was stirred at
300 rpm and kept at 37 C by a circulating water system (Ecoline
003, E100 from Lauda, Germany). The receiving solution was also
perfused continuously at 3 mL/h using a peristaltic pump (Pump
Pro MPL580 – Watson-Marlow Bredel Pumps, United Kingdom).
Samples were collected automatically every hour (Fraction collec-
tor PTFCII-Pharmatest, Germany), and the amount of drug that per-
meated the skin, i.e., the amount of drug in the receiving solution,
was analyzed as following described.
‘‘Passive’’ experiments were also performed. In that case, all
conditions were identical to those described above except that
no current was applied.2.5. Sets of in vitro iontophoretic experiments performed
The cationic porphyrin TMPyP was incorporated into the non-
ionic HEC gel at pH 5.5 and its anodal transport was measured as
a function of drug concentration and ionic strength. Thus, two sets
of experiments were performed for this drug. In the ﬁrst series, the
TMPyP anodal transport was measured from the HEC gel contain-
ing 89.5 mM of NaCl and different concentrations of the drug
(5.0, 2.5 and 1.0 mg/g, corresponding to 7.5, 3.7 and 1.5 mM). In
the second series, anodal transport of the drug at 5.0 mg/g was
evaluated from the gel in the total absence of NaCl.
The TPPS4 formulation comprised a HEC gel containing 5.0 mg/g
(5.3 mM) of the drug (TPPS4), without NaCl, at pH 5.5. The ionto-
phoretic transport of this negative porphyrin was evaluated as a
function of the polarity of the electrode compartment to evaluate
electroosmosis and electrorepulsion contributions.Fig. 2. Picture illustrating the in vivo experiments involving anodal iontophoresis of
TMPyP performed in animal models.2.6. Quantitative analysis
Both of the drugs were quantiﬁed using a UV/Vis Spectropho-
tometer (Femto-800XI). A linear calibration graph (y = 0.186x +
0.004; r = 0.999) was obtained over the working concentration
range of 0.1–1.0 lg/mL at 423 nm for TMPyP. The intra- and in-
ter-day precision and accuracy of this method showed a coefﬁcient
of variation (CV%) and relative error (E%) not greater than 3.0% and
3.7%, respectively. It was also sensitive and selective during all of
the analyses: the selectivity of the method was tested by the anal-
ysis of the receiving solution UV/Vis spectra when no drug was
administered (blank experiment).
The method used to quantify the TPPS4 had already been vali-
dated by our group [4]. A linear calibration graph for this drug(y = 0.274x + 0.001; r = 0.999) was also obtained over the working
concentration range of 0.1–1.0 lg/mL at 412 nm.
2.7. Data analysis
At least 5 replicates of each experiment were used. Results are
presented in text as means ± standard deviations (SD). Data were
evaluated statistically using analysis of variance (ANOVA), and
the Student’s t-test was used to compare two data sets. Statistical
signiﬁcance was ﬁxed at P < 0.05.
2.8. In vivo iontophoresis
TMPyP and TPPS4 skin penetration after passive and iontopho-
retic in vivo experiments was investigated in male Wistar rats that
were four weeks old (‘‘Biotério Central’’, University of São Paulo,
Brazil). The animals were housed at 24–26 C, exposed to daily
12:12 h light:dark cycles (lights on at 6 a.m.) and had free access
to standard rat chow and tap water. The animal protocol was ap-
proved by the University of São Paulo Animal Care and Use Com-
mittee (Authorization number: 06.1.492.53.9).
The hair on the abdominal skin of the animals was trimmed
48 h before the experiments. A few minutes before the gel admin-
istration, the rats were anesthetized with an intraperitoneal injec-
tion of ketamine (50 mg/kg) and xylazine (10 mg/kg) and placed on
their back. HEC gel formulation (1.0 g) containing 5.0 mg/g of
TMPyP or TPPS4, both at pH 5.5, was applied to the skin surface
of the animals via an open glass chamber (1.03 cm2) and sealed
to the skin with silicone grease. Ag or AgCl electrode (for TMPyP
or TPPS4, respectively) was then introduced and maintained at
least 5 mm from the skin surface. Negative electrode patches (Re-
turn electrode patch, Iomed Inc., Salt Lake City, USA) (Fig. 2) or Ag
electrode embedded in buffer (for TMPyP or TPPS4, respectively)
was used as counter-electrodes. A Phoresor II (model PM 850,
Iomed Inc., Salt Lake City, USA) delivered a constant current of
0.5 mA for 10 min. At the end of the experiment, the rats were sac-
riﬁced with carbon dioxide vapor. The drug-exposed skin areas
were cleaned with cotton soaked in water and removed from the
animals for analysis by ﬂuorescence microscopy (Zeiss Axioskop)
with a suitable barrier ﬁlter (470–520 nm) (Microaktueal). For this
operation, the sample ﬂuorescence was preserved by applying Tis-
sue-Tek (O.C.T. Compound) solution and freezing in liquid nitro-
gen. Cryosections (16 lm) were made with a cryomicrotome
(Microm D-6900, Heidelberg, Germany) and, subsequently, all
slices were mounted in a p-phenylenediamine mounting medium
to support ﬂuorescence stability and to protect slices against
photobleaching effects. Skin slices were then ﬂuorimetrically
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microscope camera system and a 4000x objective (Zeiss Plan-
Neoﬂuar).Fig. 3. Passive and anodal iontophoretic permeation proﬁles of TMPyP across
porcine skin from a HEC non-ionic gel containing 5.0 mg/g TMPyP and 89.5 mM
NaCl at pH 5.5 (mean ± SD; n = 5).3. Results and discussion
The porphyrins studied in the present work have shown many
stimulating results as PS drugs for PDT. The TMPyP, for example,
has excellent selectivity for neoplasic tissue [6,7,25], and TPPS4
provides excellent yields of singlet oxygen [4,12,26]. Both com-
pounds present tetrapyrrolic macrocyclic structures (Fig. 1), but
different side chains, which confers opposite electrical charges to
them. At pH 5.5, TPPS4 molecules are non-protonated ðH2TPPS44 Þ,
presenting four net negative charges. TMPyP on its turn presents
four positive charges (H2TMPyP4+) at any pH between 1.5 and 12.5.
It is important to point out that porphyrins only permeate the
skin when they are in their monomeric forms, as aggregation could
prevent skin transport [4]. The aggregation of charged porphyrins
depends on the pH of the formulation, on the presence of other
ions and on their concentration. At the pH of the experiments
(pH 5.5), the molecules are not aggregated [26–28]. It is also
assumed that the hydrogel formulation employed to incorporate
the drugs (HEC gel) for iontophoresis did not drain during its
contact with the electrodes, yet permitted the passage of the
electric current.
3.1. Electrical stability
The dosage and pH analysis of the samples guarantee that the
charged porphyrins will be stable during all of the iontophoretic
permeation experiments. The reminiscent percentage of TMPyP
(102 ± 12%) and TPPS4 (98 ± 10%) and their pH values (5.57 ± 0.07
and 5.62 ± 0.14, respectively) after 6 h of current application were
not statistically different from those parameters analyzed
previously in the beginning of the experiment (pH 5.58 ± 0.11 for
TMPyP and pH 5.82 ± 0.10 for TPPS4). No difference between the
UV/Vis spectra of the porphyrins before and after the current
application was observed (data not shown), proving that there
were no changes in the chemical properties of the compounds after
the current application.
3.2. In vitro iontophoresis
Positive molecules in contact with the anode at pH levels near
physiological values are expected to be transported through the
skin by iontophoresis due to two main mechanisms: (i) electromi-
gration, in which the positively charged drug is repulsed through
the skin by the positive electrode (anode), and (ii) electroosmosis,
as at pH levels higher than 4.0, the skin is negatively charged and is
cation permselective (1). Thus, current passage causes a net con-
vective solvent ﬂow in the anode-to-cathode direction, facilitating
the transport of molecules despite their electrical charge
[1,15,16,23,29]. It is thereby expected that TMPyP, with its positive
electric charges, has its topical delivery favored by anodal ionto-
phoresis by taking advantage of these two mechanisms, while
the negatively charged TPPS4 penetrates the skin only due to
electroosmosis when in contact with the anode and only by
electrorepulsion when in contact with the cathode.
3.2.1. TMPyP iontophoresis
TMPyP passive permeation, i.e., in vitro skin permeation of this
drug without electric current application, from the HEC gel with
89.5 mM NaCl and 7.5 mM (5.0 mg/g) of the drug showed mild
TMPyP transport across the skin. When the same formulation was
placed in contact with the anode in the presence of a 0.5 mA/cm2electric current, a signiﬁcant TMPyP skin permeation improvement
was reached, with an approximately 6-fold increase over its passive
permeation after the 6 h of experiment (Fig. 3). These results are
expected when a positive drug is iontophoretically delivered.
Considering only experiments with the most currently used drugs
in topical PDT (ALA and its derivatives, as examples), a series of
positively charged ALA esters were submitted to the anodal
iontophoresis, and a 50-fold higher ﬂux over passive transport was
observed for the methyl-ALA aqueous solution [16]. As the size
and lipophilicityof the ester increased, theefﬁciencyof electrotrans-
port decreased. Iontophoresis of methyl-ALA from hydrophilic gels
also showed around a 20-fold improvement over passive perme-
ation when the anodal iontophoresis was applied [30].
Fig. 3 shows that passive and iontophoretic deliveries of TMPyP
showed similar permeation proﬁles until the third hour of experi-
ment, but from this time iontophoresis was able to dramatically in-
crease the permeation of the positive porphyrin. It seems therefore
that the lag time in passive conditions were not achieved in those
6 h of experiments, in contrast with iontophoresis in which it was
achieved after 3 h. We decided then to choose the last hour of the
experiment (6 h) to compare passive and iontophoretic delivery of
the porphyrins.
To evaluate the drug concentration effect on TMPyP anodal ion-
tophoresis, HEC gel formulations containing (i) 1.5, (ii) 3.7 and (iii)
7.5 mM of the drug with 89.5 mM NaCl at pH 5.5 were placed in
the anode. The TMPyP iontophoretic ﬂux, calculated from the third
hour of experiment, was linearly increased with the drug concen-
tration increase (r = 0.99), as can be seen in Fig. 4. Marro et al.
[31] and Lopez et al. [15] also evaluated in vitro the transdermal
iontophoresis of lidocaine and ALA, respectively, as a function of
the concentration of drug in donor solution, and both of them
achieved signiﬁcant drug delivery improvement by increasing the
concentration in the anodal formulation. The linear increase in
TMPyP iontophoretic delivery with the concentration only occurs
because there are other ions in the anode, such as Na+, which
compete with the drug for transport through the skin. Increasing
the drug concentration increases the drug ions in the donor
compartment that compete proportionally with other ions in this
compartment. This proportionality, however, does not always
occur. Nair and Pachangnula [32] studied the effect of concentra-
tion on the iontophoretic ﬂux of arginine-vasopressine during
anodal iontophoresis and obtained a linear relationship, although
Fig. 4. Anodal iontophoretic ﬂuxes of TMPyP across porcine skin as a function of its
concentration in the donor chamber (1.0, 2.5 and 5.0 mg/g) (mean ± SD; n = 5).
Linear regression (calculated from a x–y scatter plot): y = 74.65x + 2.74, where
y = iontophoretic ﬂux of TMPyP and x = TMPyP percentage in donor chamber;
(r) = 0.99. All of the formulations were comprised of an HEC gel with 89.5 mM NaCl
at pH 5.5.
Fig. 5. Anodal iontophoretic ﬂuxes of TMPyP across porcine skin from the HEC gel
with 5.0 mg/g of TMPyP at pH 5.5 in the presence and absence of 89.5 mM NaCl
(mean ± SD; n = 5).
Fig. 6. Passive, cathodal and anodal iontophoretic ﬂuxes of across porcine skin from
a HEC gel containing 5.0 mg/g of drug at pH 5.5 (mean ± SD; n = 5).
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yet proportional. In such cases, it was assumed that the pores of
the skin may have been saturated when higher concentrations of
the drug were transported by iontophoresis, decreasing the elec-
troosmotic contribution. Therefore, it seems that TMPyP does not
interact with the skin or saturate its pores, at least at the concen-
trations studied, as the iontophoretic ﬂux was directly proportional
to drug ion concentration. Electrorepulsion seems to be the domi-
nant mechanism in this case, estimated to account for 80% of total
iontophoretic transport [33].
The inﬂuence of ionic strength on TMPyP skin permeation was
also studied because it is known that the presence of molecules
or ions that could compete with the drug by current transport
must reduce the electrorepulsive drug ﬂux through the skin
[15,17,23,34]. Therefore, an HEC gel formulation containing only
7.5 mM of TMPyP without NaCl, at pH 5.5, was placed in the anode
compartment and its iontophoresis was evaluated. In Fig. 5, it can
be observed the competitive ion absence signiﬁcantly increased
(P < 0.05) TMPyP iontophoretic transport through the skin. The ﬂux
increase was on the order of 29%. Marro et al. [31] also observed
that in the absence of competitive ions, the iontophoretic transport
of lidocaine, propanolol and quinine was independent of their con-
centration in the donor chamber. This occurs because the drug
molecules are the only cationic species in the system able to trans-
port current through the skin. It is important to point out that
although 89.5 mM NaCl is the calculated amount that provides
chloride ions for assuring the Ag electrode reactions, in the absence
of the salt, the system voltage was constantly monitored and
showed no signiﬁcant changes, meaning the electrode reaction
was occurring. The chloride ions that come from the skin towards
the anode during the iontophoresis must be supporting this reac-
tion during the experiment.
3.2.2. TPPS4 iontophoresis
We have already studied the transdermal permeation of TPPS4
as a function of its concentration, pH and ionic strength of the
aqueous solutions [4]. The protonation of this molecule in acidic
media drastically changes its spectral and energetic properties
[12], as well as its skin penetration [4]. The presence of NaCl in
aqueous solution at physiological pH also affects TPPS4 skin pene-tration, signiﬁcantly improving its passive transdermal permeation
[4]. In the present work, to evaluate only the inﬂuence of the ion-
tophoresis without the contribution of the passive ﬂux and to com-
pare this result to the iontophoresis of the cationic TMPyP
porphyrin, the salt was not added to the drug donor gel formula-
tion. In this way, the iontophoretic ﬂux of the porphyrins in study
can be compared despite the differences in their initial donor con-
centration because it is known that in the absence of competitive
ions the iontophoretic transport is independent of drug concentra-
tion in the donor chamber [31]. Note that iontophoresis of TPPS4
was investigated at 5.3 mM (5 mg/g), and not at 7.5 mM because
TPPS4 precipitate in the gel at this last molar concentration.
It is shown in Fig. 6 that the passive permeation of TPPS4 from
HEC gel was very low. When cathodal iontophoresis was applied,
electrorepulsion between the negative charges of the molecule
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6 h increased 3-fold over its passive permeation (Fig. 6). When
compared to TMPyP iontophoresis, the iontophoretic amount of
TPPS4 permeated after 6 h was 67-fold lower (Table 1). However,
over anodal iontophoresis of TMPyP, both electroosmotic and elec-
trorepulsive ﬂuxes contributed to its iontophoretic transport, but
during cathodal iontophoresis of TPPS4, only an electrorepulsive
ﬂux transports this drug through the skin since electroosmotic
contributions are in the anode-to-cathode direction at pH 5.5
[4,23]. Because it is known that the electroosmotic ﬂux of any sub-
stance is independent of its molecular weight and charge density
[16,23], the anodal iontophoresis of TPPS4 was studied to verify
how much electroosmotic ﬂux would improve the permeation of
TPPS4.
Fig. 6 shows that the anodal iontophoretic ﬂux of TPPS4 is not
signiﬁcantly different from its passive ﬂux (P > 0.05). The inefﬁ-
ciency of anodal iontophoresis, i.e. of electroosmosis, in improving
the permeation of TPPS4 must be related to the electro-attraction
that occurs between its charges and those of the positive electrode.
Equally, Sylvestre et al. [22] studied the iontophoresis of the nega-
tively charged dexamethasone phosphate and veriﬁed that its
delivery from the anode was really inefﬁcient for clinical purposes
due to similar reasons as the observed in this work.
It is interesting to note that TPPS4 iontophoretic permeation
proﬁle was very similar to its passive permeation one (Fig. 6), in
contrast to the TMPyP iontophoretic permeation that clearly re-
duced drug’s lag time when compared to the passive condition.
From Fig. 6, it is possible to draw two opposing hypothesis about
TPPS4 lag time: (1) it is smaller than 1 h after passive and ionto-
phoretic delivery and (2) the steady state was not achieved during
the period of the experiment. It is hardly to believe that a charged
molecule with a relatively high-molecular-weight (MWTPPS4 =
935.4 Da) would present a lag time smaller than 1 h. Therefore,
we believe that the steady state for TPPS4 was not attained during
the 6 h of experiment, but longer period of diffusion would be nec-
essary to prove that. In this work, however, we performed only 6 h
of iontophoresis because one can increase drug permeation with-
out compromising skin’s barrier properties during this period of
experiment [35].
In summary, under the studied conditions, passive permeation
of TPPS4 was about 20-fold lower than that of TMPyP after 6 h of
experiment. The main reasons for this reduced passive permeation
are the higher molecular weight of TPPS4, as well as its four nega-
tive charges at pH 5.5, which make difﬁcult its diffusion through
the negatively charged skin at this pH [4,26]. Electrorepulsive ﬂux
contributed to a 3-fold increase over TPPS4 passive permeation
after 6 h, while TMPyP anodal iontophoresis (electrorepulsive plus
electroosmosis) increased 12 times the permeation of this drug.
Anodal iontophoresis had no effect on the transport of TPPS4.
Therefore, the contribution of the electrosmotic ﬂux for a highly
anionic drug must be counterbalanced by other electrostatic phe-
nomenon that may occur during iontophoresis, as drug attraction
by the electrode of the same polarity, and repulsion between the
H2TPPS
4
4 and the known negatively charged stratum corneum of
the skin [14] obstructing its skin penetration even when the ionto-Table 1
Positive and negative porphyrins delivered in vitro after 6 h of passive and
iontophoretic experiments. Both formulation comprised a HEC gel contained only
5.0 mg/g of porphyrin at pH 5.5.
Porphyrin Passive (nmol/cm2) Iontophoresis (nmol/cm2)
TMPyP 23.4 (±4.2) 276.9 (±57.5) [Anodal]
TPPS4 1.2 (±0.3) 4.1 (±0.4) [Cathodal]
*Values are presented as means ± SD of 5 replicates.phoresis is applied. The calculated electrorepulsive contribution
for TMPyP (calculated by subtracting the passive and the electros-
motic contributions, the last one estimated to be 20% of the total
iontophoretic ﬂux [33]) was around 70-fold higher than the calcu-
lated electrorepulsive contribution for the negative porphyrin (cal-
culated by the difference between the cathodal iontophoretic
amount and the passive amount). In this context, the iontophoresis
of the positively charged tetrapyrrolic macrocycle TMPyP was
much greater than that of the structurally similar, but negatively
charged TPPS4. Therefore, the study of the contribution of elect-
rorepulsion for highly charged cationic (+4) and anionic (4)
drugs, in a speciﬁc pH, indicated that iontophoretic contribution,
speciﬁcally the electrorepulsive one, is much more relevant for
skin penetration of cationic than for similar, but anionic, drugs,
at pH 5.5.
To verify the drugs distribution in the skin after passive and ion-
tophoretic administration, in vivo experiments were performed, as
discussed below.
3.3. In vivo iontophoresis
Iontophoretic in vitro experiments clearly showed that the stud-
ied porphyrins can overcome the stratum corneum barrier in
greater amounts than through passive delivery. The presence and
distribution of these drugs in the viable epidermis, the real site
of interest in PDT, can be better evaluated by in vivo experiments
since these layers of the skin are not viable in the in vitro experi-
ments performed [36]. Also, there is no proportionality between
the amount of drug accumulated inside the tissue and the amount
permeated into the receptor compartment when iontophoresis is
applied [4]. Therefore, to analyze how deep TMPyP and TPPS4 pen-
etrate into the skin after a short period of electrical current appli-
cation and their tissue distribution, the porphyrin ﬂuorescence was
analyzed in vivo in Wistar rats after passive and anodal iontopho-
resis for TMPyP and passive and cathodal iontophoresis for TPPS4
from gel formulations at 5.0 mg/g in the absence of NaCl at pH 5.5.
As can be seen in Fig. 7B, 10 min of passive permeation of the
negatively charged TPPS4 did not change the blue ﬂuorescence of
the skin. The application of cathodal iontophoresis (0.5 mA/cm2)
on the TPPS4 formulation for the same period of time made possi-
ble the visualization of ﬂuorescence, typical of the PS studied, only
in the superﬁcial layers of the skin (Fig. 7C). In our previous work,
the in vivo iontophoresis of TPPS4 was also performed under the
same experimental conditions, except for the presence of NaCl in
the formulation. According to Aggawarl and Borissevitch [26], at
neutral pH, NaCl addition can bind TPPS4 molecules, forming
[TPPS4  nNa+] complexes that partially neutralize the negative
charge of H2TPPS
4
4 . The in vivo iontophoretic permeation of TPPS4
in this case (in the presence of NaCl) was expressive, showing ﬂuo-
rescence throughout the whole skin tissue [4]. These results cor-
roborate the theory that the negative charges of the TPPS4
molecule are the major factor responsible for its passive and ionto-
phoretically low skin penetration.
On the other hand, the presence of positive charges in the tetra-
pyrrolic macrocycle increased the passive and the iontophoretic
delivery of TMPyP. In Fig. 7D, the TMPyP ﬂuorescence can be ob-
served in the superﬁcial layers of the skin after 10 min of the pas-
sive experiment. Iontophoresis expressively increased the rat
epidermis and dermis ﬂuorescence, indicating high amounts of
the drug was able to cross the SC barrier throughout the entire skin
(Fig. 7E). In addition, it can be seen in the photomicrographs that
TMPyP was homogeneously distributed around and into the nuclei
of the skin cells. The accumulation of TMPyP at such cellular sites is
advantageous for PDT because its photodynamic action is achieved
as soon as it forms DNA complexes in the nuclei of the cutaneous
cells [6,8,9].
Fig. 7. Fluorescence microscopy photomicrographs of vertical slicing of Wistar rat skin before (A) and after 10 min of passive (B) and anodal iontophoresis (C) of a HEC gel
containing 5.0 mg/g TPPS4 at pH 5.5; and after 10 min of passive (D) and anodal iontophoresis (E) of a HEC gel containing 5.0 mg/g TMPyP. EP. Epidermis; DE. Dermis. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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permeation route for drugs delivered by iontophoresis [37], and
as Wistar rats are hairier than other skin models as porcine and
human skin, the performance of this technique showed in the
present work could be lower if a different animal model was
used.
In conclusion, iontophoretic studies with the positively charged
tetrapyrrole macrocycle TMPyP showed the expected results: a sig-
niﬁcant improvement in drug transdermal permeation when com-
pared to passive permeation, signiﬁcant TMPyP delivery by
increasing the drug concentration in the anodal formulation and
an enhanced drug amount delivered when the background electro-
lyte concentration was lowered. On the other hand, despite the fact
that the cathodal iontophoretic delivery of the negatively charged
tetrapyrrole macrocycle had improved TPPS4 ﬂux over passive
permeation, this drug permeation was, both in passive and in ion-
tophoretic experiments, much smaller than the positive drug per-
meation. In vivo experiments conﬁrmed this difference by showing
a deeper skin penetration and a homogeneous distribution of the
positive TMPyP over the H2TPPS
4
4 when anodal iontophoresis
was employed. These results suggest that the iontophoresis of
TMPyP is a promising technique for topical PDT.Acknowledgments
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